Home/Pipeline/ALN-HBV02 (VIR-2218)

ALN-HBV02 (VIR-2218)

Chronic Hepatitis B Virus Infection

Phase 2Active (Partnered with Vir Bio)

Key Facts

Indication

Chronic Hepatitis B Virus Infection

Phase

Phase 2

Status

Active (Partnered with Vir Bio)

Company

Alnylam Pharmaceuticals

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals' mission is to harness RNA interference (RNAi) to develop transformative medicines for patients with serious diseases. The company has achieved its goal of building a sustainable, top-tier biopharmaceutical company, with five FDA-approved products generating significant revenue and a deep clinical pipeline. Its strategy, 'Alnylam 2030,' focuses on expanding into prevalent diseases, advancing next-generation platforms, and scaling global commercial and manufacturing operations to serve millions of patients.

View full company profile

Therapeutic Areas

Rare Genetic Diseases Cardio-Metabolic Diseases Hepatic Infectious Diseases Central Nervous System (CNS) Diseases Ocular Diseases

Other Chronic Hepatitis B Virus Infection Drugs

Drug	Company	Phase	Status
DCR-HBVS	Dicerna Pharmaceuticals	Preclinical	Collaboration Terminated (Roche)
ISA104	ISA Pharmaceuticals	Phase 1/2a	Active